This is a preview of subscription content, log in via an institution to check access.
Notes
2019 Canadian dollars
References
1. Di Maio D, et al. Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Relapsing Remitting Multiple Sclerosis. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND39, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/110409
2. Di Maio D, et al. Socioeconomic Value of Ocrelizumab in the Treatment of Patients with Primary Progressive Multiple Sclerosis. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND16, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/110633
Rights and permissions
About this article
Cite this article
Ocrelizumab offers socioeconomic benefits for MS in Canada. PharmacoEcon Outcomes News 880, 22 (2021). https://doi.org/10.1007/s40274-021-7780-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7780-2